Efemoral Medical, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Efemoral Medical, Inc.
The EFEMORAL I trial is the first-in-human study of the start-up company’s FlexStep technology in patients with symptomatic femoropopliteal artery disease.
The $320k grant will support research that builds on IQuity’s autoimmune diagnostic expertise and new data analytics platform. The company believes the emerging therapies for Alzheimer's will be most effective if they are used to treat the disease early in its progression.
Nashville-based genomics company iQuity is building a data mining and analytics platform that will predict and monitor chronic diseases from public and private datasets from large populations.
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Venture Funding Deals column provides a comprehensive monthly review of emerging life science companies that have received venture funding, including companies within the In Vitro Diagnostics, Medical Devices, Pharmaceuticals, and Research, Analytical Equipment and Supplies sectors. This month’s column covers deals announced December 2015 through January 2016.
- Implantable Devices